logo-loader
viewAvacta Group PLC

Avacta says expanded LG Chem collaboration could trigger further "substantial" payments

The company is a specialist in developing Affimers, which are engineered proteins that help drugs more effectively target diseases such as cancer

Avacta Group PLC -
Avacta chief executive Alastair Smith said the first LG drug programme had made “excellent progress”

Avacta Group PLC (LON:AVCT) has taken an “important step” towards further “substantial” milestone payments from the drug development arm of the Korean giant LG by expanding its partnership.

Avacta is a specialist in developing Affimers, which are engineered proteins that help drugs more effectively target diseases such as cancer.

It has been working with LG Chem Life Sciences to find a protein to bind to one of its discoveries.

The latest update reveals that LG Chem has now nominated two further prospective treatments that will use the UK group’s technology.

Avacta chief executive Alastair Smith said the first LG drug programme had made “excellent progress”, and was upbeat on the expanded collaboration.

Important validation 

“Not only is this an important validation of the Affimer platform, confirming that it can be used to quickly generate potential candidate drug molecules for development, but it also means that we have taken an important step towards receiving the next substantial milestone payment under our collaboration agreement,” he explained.

“Our partnership with LG Chem goes from strength to strength with their decision to nominate the next two drug targets. I look forward to keeping the market informed of further progress over the coming months."

Avacta has developed scaffolds called Affimers, which are essentially small, engineered proteins capable of binding specific molecular targets, in a similar way to antibodies.

This binding property can be used to target cancer cells in the human body and make those cells vulnerable to attack from the body’s own immune system.

Many existing immuno-oncology therapies use an antibody to target cancer, but Affimers have several innovative features which potentially make them a better tool for several diagnostic and therapeutic applications.

Smaller and quicker 

They are smaller, quicker to manufacture and easier to format, but they maintain antibody-like biologic activity when binding a target.

Avacta is using Affimers to develop various potential cancer treatments, while other companies pay to use the technology in their research and diagnostics.

 

Quick facts: Avacta Group PLC

Price: 20.1 GBX

AIM:AVCT
Market: AIM
Market Cap: £35.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Avacta Group heading into 'crucial year' for its cancer therapeutics programmes

Proactive Research analyst Ed Stacey says Avacta (LON:AVCT) is preparing for a crucial year in its cancer therapeutics programmes in 2020, with an opportunity now identified for a targeted chemotherapy programme to enter clinical trials during the first half. Stacey says alongside the recent...

on 23/10/19

2 min read